Peer-reviewedCC BYMolecular Therapy: Oncology
PARP7 inhibitors enhance the immunogenic effects of radiation in pancreatic cancer cells
Abstract
, and interferon response genes. PARP7i potentiated the immunogenic effects of hypofractionated radiation by inducing a STING-dependent IFN-I response, leading to immunogenic cell death and activation of monocytes and NK cells. Carbon ion irradiation elicited stronger immunogenicity than X-rays when combined with PARP7i. KRAS-mutated PANC-1 cells showed a higher expression of enzymes that convert ATP to immunosuppressive adenosine, which was enhanced by radiation. This may explain why PARP7i were more effective as monotherapy in PANC-1 cells, promoting NK cell activation. These findings support further evaluation of PARP7i in PDAC in combination with radiotherapy or as monotherapy, depending on the immunosuppressive effects of radiation.
Related
- Mitophagy-dependent mitochondrial DNA release links ionizing radiation to immunogenic cell death in pancreatic cancer
- ATR inhibition sensitizes pancreatic cancer cells to cytotoxic and immunogenic effects of X-ray and carbon ion irradiation
- Parent-of-Origin-Aware Genomic Analysis to Enhance Cascade Testing in Pancreatic Cancer: A Population-Based Study
- Optimized dosing of spatially heterogeneous radiopharmaceutical therapy reprograms poorly immunogenic tumors to enhance response to immune checkpoint blockade
- ERG inhibition selectively sensitizes ERG-positive prostate cancer to radiation through DNA repair vulnerabilities and enhances response to androgen receptor inhibitors.
BibTeX
@article{bragato2026parp7,
title = {{PARP7 inhibitors enhance the immunogenic effects of radiation in pancreatic cancer cells}},
author = {Niccolò Bragato and Ana Beatriz Dias and Anna Ohradanova-Repic and Alma Dupanovic and Filip Horvat and Patrick Fischer and Lisa-Marie Appel and Lena Walch and Ava Kleinwächter and Anna Röhrer and Sylvia Kerschbaum-Gruber and Sandra Barna and Piero Fossati and Dietmar Georg and Joachim Widder and Klaus Podar and Michael Cohen and Dea Slade},
journal = {Molecular Therapy: Oncology},
year = {2026},
month = oct,
doi = {10.1016/j.omton.2026.201258},
url = {https://hal.science/hal-05787608v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - PARP7 inhibitors enhance the immunogenic effects of radiation in pancreatic cancer cells
AU - Niccolò Bragato
AU - Ana Beatriz Dias
AU - Anna Ohradanova-Repic
AU - Alma Dupanovic
AU - Filip Horvat
AU - Patrick Fischer
AU - Lisa-Marie Appel
AU - Lena Walch
AU - Ava Kleinwächter
AU - Anna Röhrer
AU - Sylvia Kerschbaum-Gruber
AU - Sandra Barna
AU - Piero Fossati
AU - Dietmar Georg
AU - Joachim Widder
AU - Klaus Podar
AU - Michael Cohen
AU - Dea Slade
PY - 2026
DA - 2026/10/08
JO - Molecular Therapy: Oncology
DO - 10.1016/j.omton.2026.201258
UR - https://hal.science/hal-05787608v1
AB - , and interferon response genes. PARP7i potentiated the immunogenic effects of hypofractionated radiation by inducing a STING-dependent IFN-I response, leading to immunogenic cell death and activation of monocytes and NK cells. Carbon ion irradiation elicited stronger immunogenicity than X-rays when combined with PARP7i. KRAS-mutated PANC-1 cells showed a higher expression of enzymes that convert ATP to immunosuppressive adenosine, which was enhanced by radiation. This may explain why PARP7i were more effective as monotherapy in PANC-1 cells, promoting NK cell activation. These findings support further evaluation of PARP7i in PDAC in combination with radiotherapy or as monotherapy, depending on the immunosuppressive effects of radiation.
SN - 2950-3299
ER -